Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event - PubMed (original) (raw)
. 2003 Jul 10;349(2):139-45.
doi: 10.1056/NEJMoa022328.
Affiliations
- PMID: 12853586
- DOI: 10.1056/NEJMoa022328
Free article
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event
Thomas Berger et al. N Engl J Med. 2003.
Free article
Abstract
Background: Most patients with multiple sclerosis initially present with a clinically isolated syndrome. Despite the fact that clinically definite multiple sclerosis will develop in up to 80 percent of these patients, the course of the disease is unpredictable at its onset and requires long-term observation or repeated magnetic resonance imaging (MRI). We investigated whether the presence of serum antibodies against myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) in patients with a clinically isolated syndrome predicts the interval to conversion to clinically definite multiple sclerosis.
Methods: A total of 103 patients with a clinically isolated syndrome, positive findings on cerebral MRI, and oligoclonal bands in the cerebrospinal fluid were studied. At base line, serum samples were collected to test for anti-MOG and anti-MBP antibodies with Western blot analysis, and the lesions detected by cerebral MRI were quantified. Neurologic examinations for relapse or disease progression (defined as conversion to clinically definite multiple sclerosis) were performed at base line and subsequently every three months.
Results: Patients with anti-MOG and anti-MBP antibodies had relapses more often and earlier than patients without these antibodies. Only 9 of 39 antibody-seronegative patients (23 percent) had a relapse, and the mean (+/-SD) time to relapse was 45.1+/-13.7 months. In contrast, 21 of 22 patients (95 percent) with antibodies against both MOG and MBP had a relapse within a mean of 7.5+/-4.4 months, and 35 of 42 patients (83 percent) with only anti-MOG antibodies had a relapse within 14.6+/-9.6 months (P<0.001 for both comparisons with antibody-seronegative patients). The adjusted hazard ratio for the development of clinically definite multiple sclerosis was 76.5 (95 percent confidence interval, 20.6 to 284.6) among the patients who were seropositive for both antibodies and 31.6 (95 percent confidence interval, 9.5 to 104.5) among the patients who were seropositive only for anti-MOG antibodies, as compared with the seronegative patients.
Conclusions: Analysis of antibodies against MOG and MBP in patients with a clinically isolated syndrome is a rapid, inexpensive, and precise method for the prediction of early conversion to clinically definite multiple sclerosis. This finding may be important for the counseling and care of patients with a first demyelinating event suggestive of multiple sclerosis.
Copyright 2003 Massachusetts Medical Society
Comment in
- Do myelin-directed antibodies predict multiple sclerosis?
Antel JP, Bar-Or A. Antel JP, et al. N Engl J Med. 2003 Jul 10;349(2):107-9. doi: 10.1056/NEJMp030098. N Engl J Med. 2003. PMID: 12853581 No abstract available. - Antimyelin antibodies in multiple sclerosis.
Maguire GA. Maguire GA. N Engl J Med. 2003 Dec 4;349(23):2269-71; author reply 2269-71. doi: 10.1056/NEJM200312043492321. N Engl J Med. 2003. PMID: 14657439 No abstract available. - Antimyelin antibodies in multiple sclerosis.
Mantegazza R. Mantegazza R. N Engl J Med. 2003 Dec 4;349(23):2269-71; author reply 2269-71. N Engl J Med. 2003. PMID: 14663868 No abstract available. - Antimyelin antibodies in multiple sclerosis.
Chaudhuri A, Behan PO. Chaudhuri A, et al. N Engl J Med. 2003 Dec 4;349(23):2269-71; author reply 2269-71. N Engl J Med. 2003. PMID: 14663869 No abstract available.
Similar articles
- Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS.
Tomassini V, De Giglio L, Reindl M, Russo P, Pestalozza I, Pantano P, Berger T, Pozzilli C. Tomassini V, et al. Mult Scler. 2007 Nov;13(9):1086-94. doi: 10.1177/1352458507077622. Epub 2007 Apr 27. Mult Scler. 2007. PMID: 17468447 - Antimyelin antibodies with no progression to multiple sclerosis.
Pelayo R, Tintoré M, Montalban X, Rovira A, Espejo C, Reindl M, Berger T. Pelayo R, et al. N Engl J Med. 2007 Jan 25;356(4):426-8. doi: 10.1056/NEJMc062467. N Engl J Med. 2007. PMID: 17251547 No abstract available. - Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event.
Rauer S, Euler B, Reindl M, Berger T. Rauer S, et al. J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):739-42. doi: 10.1136/jnnp.2005.077784. J Neurol Neurosurg Psychiatry. 2006. PMID: 16705196 Free PMC article. - The myelin-associated oligodendrocytic basic protein (MOBP) as a relevant primary target autoantigen in multiple sclerosis.
Kaushansky N, Eisenstein M, Zilkha-Falb R, Ben-Nun A. Kaushansky N, et al. Autoimmun Rev. 2010 Feb;9(4):233-6. doi: 10.1016/j.autrev.2009.08.002. Epub 2009 Aug 13. Autoimmun Rev. 2010. PMID: 19683076 Review. - Antibodies as biological markers for pathophysiological processes in MS.
Reindl M, Khalil M, Berger T. Reindl M, et al. J Neuroimmunol. 2006 Nov;180(1-2):50-62. doi: 10.1016/j.jneuroim.2006.06.028. Epub 2006 Aug 23. J Neuroimmunol. 2006. PMID: 16934337 Review.
Cited by
- Age-Related Decline in Brain Myelination: Quantitative Macromolecular Proton Fraction Mapping, T2-FLAIR Hyperintensity Volume, and Anti-Myelin Antibodies Seven Years Apart.
Khodanovich M, Svetlik M, Naumova A, Kamaeva D, Usova A, Kudabaeva M, Anan'ina T, Wasserlauf I, Pashkevich V, Moshkina M, Obukhovskaya V, Kataeva N, Levina A, Tumentceva Y, Yarnykh V. Khodanovich M, et al. Biomedicines. 2023 Dec 27;12(1):61. doi: 10.3390/biomedicines12010061. Biomedicines. 2023. PMID: 38255168 Free PMC article. - Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum.
Fialová L, Švarcová J, Bartos A, Malbohan I. Fialová L, et al. Folia Microbiol (Praha). 2012 Sep;57(5):415-9. doi: 10.1007/s12223-012-0105-x. Epub 2012 May 8. Folia Microbiol (Praha). 2012. PMID: 22566118 - [Plasma exchange as a therapeutic option in neurological disorders].
Lehmann HC, Hartung HP, Hetzel GR, Kieseier BC. Lehmann HC, et al. Nervenarzt. 2007 Feb;78(2):166, 168-70, 172-6. doi: 10.1007/s00115-006-2229-1. Nervenarzt. 2007. PMID: 17268791 Review. German. - Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.
Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Brück W, Hartung HP, Stadelmann C, Hemmer B. Zhou D, et al. Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19057-62. doi: 10.1073/pnas.0607242103. Epub 2006 Dec 1. Proc Natl Acad Sci U S A. 2006. PMID: 17142321 Free PMC article. - Evaluation of anti α-d-Glc_p_-(1→4)-α-d-Glc_p_ (GAGA4) IgM antibodies as a biomarker for multiple sclerosis.
Braganza CD, Santoso KT, Dangerfield EM, La Flamme AC, Timmer MSM, Stocker BL. Braganza CD, et al. RSC Adv. 2018 Aug 6;8(49):28086-28093. doi: 10.1039/c8ra04897e. eCollection 2018 Aug 2. RSC Adv. 2018. PMID: 35542693 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous